Skip to main content

Table 1 Clinical characteristics of the 179 DLBCL patients from 2006 to 2016

From: Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma

Characteristics

No. of cases (%)

Age (years)

 ≤60

101 (56.4)

Male

104 (58.1)

Stage III-IV

99 (55.3)

Elevated ALT (>  50 U/L)

22 (12.3)

Elevated AST (>  33.3 U/L)

44 (24.6)

Elevated LDH (>  250 U/L)

72 (40.2)

ECOG PS ≥2

28 (15.6)

ENI ≥2

43 (24.0)

IPI score of 3–5

52 (29.1)

B symptoms

62 (34.6)

COO (Hans)

 GCB

77 (43.0)

Treatment

 R-CHOP

145 (81.0%)

 R-DA-EPOCHa

14 (7.8%)

 R-CHOP-likeb

20 (11.2%)

 Radiationc

11 (6.1%)

Auto-HSCT consolidationd

15 (8.4%)

  1. Abbreviations: ALT alanine aminotransferase, IPI International Prognostic Index, AST aspartate aminotransferase, COO cell of origin, DLBCL diffuse large B-cell lymphoma, ECOG PS performance status of Eastern Cooperative Oncology Group, ENI extra nodal involvement, GCB germinal-center B-cell type, HSCT Hematopoietic Stem Cell Transplantation, LDH lactate dehydrogenase
  2. aPatients with high risk (IPI = 4–5) received R-DA-EPOCH regimen
  3. bPatients with old age (≥ 75 years old), extremely poor ECOG PS or accompanying heart disease received R-CHOP-like regimens including R-CDOP, R-CEOP and R-mini-CHOP
  4. cCases with localized residual lesions received radiotherapy after immunochemotherapy
  5. dAmong the patients who received Auto-HSCT, 8 cases were AST positive
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us